Literature DB >> 22136183

Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.

Colin John Crooks1, David Prieto-Merino, Stephen J W Evans.   

Abstract

BACKGROUND: The detection of adverse events following immunization (AEFI) fundamentally depends on how these events are classified. Standard methods impose a choice between either grouping similar events together to gain power or splitting them into more specific definitions. We demonstrate a method of medically guided Bayesian information sharing that avoids grouping or splitting the data, and we further combine this with the standard epidemiological tools of stratification and multivariate regression.
OBJECTIVE: The aim of this study was to assess the ability of a Bayesian hierarchical model to identify gastrointestinal AEFI in children, and then combine this with testing for effect modification and adjustments for confounding. STUDY
DESIGN: Reporting odds ratios were calculated for each gastrointestinal AEFI and vaccine combination. After testing for effect modification, these were then re-estimated using multivariable logistic regression adjusting for age, sex, year and country of report. A medically guided hierarchy of AEFI terms was then derived to allow information sharing in a Bayesian model.
SETTING: All spontaneous reports of AEFI in children under 18 years of age in the WHO VigiBase™ (Uppsala Monitoring Centre, Uppsala, Sweden) before June 2010. Reports with missing age were included in the main analysis in a separate category and excluded in a subsequent sensitivity analysis. EXPOSURES: The 15 most commonly prescribed childhood vaccinations, excluding influenza vaccines. MAIN OUTCOME MEASURES: All gastrointestinal AEFI coded by WHO Adverse Reaction Terminology.
RESULTS: A crude analysis identified 132 signals from 655 reported combinations of gastrointestinal AEFI. Adjusting for confounding by age, sex, year of report and country of report, where appropriate, reduced the number of signals identified to 88. The addition of a Bayesian hierarchical model identified four further signals and removed three. Effect modification by age and sex was identified for six vaccines for the outcomes of vomiting, nausea, diarrhoea and salivary gland enlargement.
CONCLUSION: This study demonstrated a sequence of methods for routinely analysing spontaneous report databases that was easily understandable and reproducible. The combination of classical and Bayesian methods in this study help to focus the limited resources for hypothesis testing studies towards adverse events with the strongest support from the data.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22136183     DOI: 10.2165/11596630-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  27 in total

1.  Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination.

Authors:  M T Niu; D E Erwin; M M Braun
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

2.  Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events.

Authors:  G Niklas Norén; Andrew Bate; Roland Orre; I Ralph Edwards
Journal:  Stat Med       Date:  2006-11-15       Impact factor: 2.373

Review 3.  Quantitative signal detection using spontaneous ADR reporting.

Authors:  A Bate; S J W Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890

4.  Stratification for spontaneous report databases.

Authors:  Stephen J W Evans
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

6.  Impact of anti-vaccine movements on pertussis control: the untold story.

Authors:  E J Gangarosa; A M Galazka; C R Wolfe; L M Phillips; R E Gangarosa; E Miller; R T Chen
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

7.  Individual versus public priorities in the determination of optimal vaccination policies.

Authors:  P E Fine; J A Clarkson
Journal:  Am J Epidemiol       Date:  1986-12       Impact factor: 4.897

8.  The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural Guinea-Bissau: an observational study.

Authors:  Peter Aaby; Henrik Jensen; Joaquim Gomes; Manual Fernandes; Ida Maria Lisse
Journal:  Int J Epidemiol       Date:  2004-04       Impact factor: 7.196

9.  An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?

Authors:  Penina Haber; Robert T Chen; Lynn R Zanardi; Gina T Mootrey; Roseanne English; M Miles Braun
Journal:  Pediatrics       Date:  2004-04       Impact factor: 7.124

10.  Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD).

Authors:  M T Niu; P Rhodes; M Salive; T Lively; D M Davis; S Black; H Shinefield; R T Chen; S S Ellenberg
Journal:  J Clin Epidemiol       Date:  1998-06       Impact factor: 6.437

View more
  3 in total

1.  Terminological challenges in safety surveillance.

Authors:  Andrew Bate; Elliot G Brown; Stephen A Goldman; Manfred Hauben
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Hierarchical Models for Multiple, Rare Outcomes Using Massive Observational Healthcare Databases.

Authors:  Trevor R Shaddox; Patrick B Ryan; Martijn J Schuemie; David Madigan; Marc A Suchard
Journal:  Stat Anal Data Min       Date:  2016-07-17       Impact factor: 1.051

3.  The Use of a Bayesian Hierarchy to Develop and Validate a Co-Morbidity Score to Predict Mortality for Linked Primary and Secondary Care Data from the NHS in England.

Authors:  Colin J Crooks; Tim R Card; Joe West
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.